News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Wyeth (WYE) Wins Philadelphia Phase II Diet Drug Cases


10/19/2005 5:13:15 PM

MADISON, N.J., April 8 /PRNewswire-FirstCall/ -- Wyeth announced today that the jury in the cases of Camille Olsen v. Wyeth and Isabel Vega v. Wyeth in the Philadelphia Court of Common Pleas found in favor of the Company in the second, liability phase of this bifurcated (two-phase) trial. Although the jury had assessed $5.5 million in potential damages during phase one of the trial, today's decision means that Wyeth has no liability in this case.

The trial began with four plaintiffs on March 21, 2005 before The Honorable Gary Glazer. Phase one of the trial was completed on March 30, with the jury finding in favor of the Company in the Marilyn Lyman v. Wyeth and Stephen Schultz v. Wyeth cases, and in favor of the plaintiffs in the Olsen and Vega cases. The plaintiffs were represented by the Fleming & Associates law firm of Houston, Texas.

The plaintiffs alleged heart valve injury from the use of Pondimin, a drug once marketed by Wyeth, and asserted that Wyeth was negligent in the information it provided about the risks and benefits of Pondimin prior to 1997.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Wyeth

CONTACT: Media - Doug Petkus of Wyeth +1-973-660-5218, or Chris Garlandof Wyeth Pharmaceuticals, +1-484-865-6323, Investors - Justin Victoria ofWyeth, +1-973-660-5340


Read at BioSpace.com

comments powered by Disqus
   
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES